Expanding Later-Line Treatment Options for Multiple Myeloma: Paul G. Richardson, MD

Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor. In this interview with i3 Health, Paul G. Richardson, MD, who served as the co-primary investigator of the ICARIA-MM study, on which the isatuximab approval was based, shares his thoughts on the si...
Continue reading

Enhancing Treatment for Patients With GIST: Michael Heinrich, MD

Because gastrointestinal stromal tumor (GIST) has an estimated incidence of 3,300 to 6,000 new cases per year in the United States, comprising less than 1% of all gastrointestinal tumors, the rarity of this tumor type can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest treatments. Michael C. Heinrich, MD, lead investigator of the phase 1 NAVIGATOR trial, recently spoke with i3 Health about the FDA's approval of avapritinib (Ayva...
Continue reading

Avapritinib for PDGFRA Exon 18-Mutated GIST: Michael Heinrich, MD

Up to 10% of patients with gastrointestinal stromal tumor (GIST) harbor platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, which have been linked to resistance to standard GIST therapies. The FDA's recent approval of avapritinib (AyvakitTM, Blueprint Medicines) for adults with unresectable or metastatic GIST with PDGFRA exon 18 mutations has given these patients a highly promising treatment option. In this interview, Michael C. Heinrich, MD, lead investigator of the phase ...
Continue reading

Utilizing Proper Supportive Care in Multiple Myeloma: An Interview With Smith Giri, MD, MHS

​In the treatment of multiple myeloma, supportive care is essential to mitigating the risks of infection and bone disease. However, a study published recently in Cancer by Smith Giri, MD, MHS, and colleagues found that guideline-recommended supportive care measures are underutilized in older patients with multiple myeloma. In this interview with i3 Health, Dr. Giri discusses supportive care for patients with myeloma, as well as interventions that could increase the use of these measures. Can you...
Continue reading

Optimizing Prostate Cancer Detection: Interview With Johannes Czernin, MD

There is a discrepancy in guideline recommendations regarding prostate cancer detection; National Comprehensive Cancer Network (NCCN) guidelines recommend using 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localization after radical prostatectomy as opposed to European Association of Urology (EAU) guidelines, which recommend prostate-specific membrane antigen (PSMA) PET-CT. Jeremie Calais, MD, Johannes Czernin, MD, and colleagues compared using 18F-fluciclovine PET-CT versu...
Continue reading

Advising Patients on Follicular Lymphoma Treatment: An Interview With Carla Casulo, MD

Receiving a cancer diagnosis can be devastating, confusing, and overwhelming. It is important for oncologists to be thorough in explaining the treatment process to patients. In this interview with i3 Health, Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, gives advice on counseling patients diagnosed with follicular lymphoma. What questions do you commonly encounter from patients or caregivers about their treatment, and how do you counsel them? Carla Casulo, ...
Continue reading

Advances in the Personalized Management of RCC With Brian I. Rini, MD, FACP

Based on recent estimates, kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 65,300 new cases are reported each year and more than 14,000 people die of the disease. Renal cell carcinoma (RCC), which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. As a result of its often asymptomatic presentation, many patients present ...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.